Galapagos’ IPF program
With GLPG1690, Galapagos discovered a novel mode of action targeting autotaxin, with potential application in idiopathic pulmonary fibrosis. GLPG1690 completed a Phase 1 first-in-human trial. The randomized, double-blind, placebo controlled, single center trial was conducted in at least 40 healthy volunteers in Belgium. In the first part of the trial, single ascending doses were evaluated. In the second part, the new compound was administered daily for 14 days. GLPG1690 proved to be safe and well-tolerated over a wide dose range in healthy volunteers. Engagement of the autotaxin target was confirmed using a relevant biomarker. GLPG1690 displayed a favorable pharmacokinetic and pharmacodynamic profile. The data shown in Phase 1 encourage Galapagos to explore a Phase 2 study design in IPF, to be filed before end 2015. GLPG1690 is wholly owned by Galapagos.